Posts Tagged ‘half-life’
July 3, 2025 — “If HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary want to bring radical transparency to U.S. healthcare, they can start by updating drug labels that lack good information for persons with larger bodies. ” In RealClearHealth yesterday, an editorial by Caroline Apovian and Ted Kyle called for policymakers at FDA to deliver […]
April 22, 2025 — Change is hard and people resist it. FDA is coming to terms with the idea of radical transparency and certainly drug labels are a good place to start. When we talk about drug labels for prescription drugs, it means the lengthy “prescribing information” that FDA reviews and approves. Its purpose is to tell doctors, pharmacists, […]
November 16, 2024 — Research presented at ObesityWeek 2024 shines a light on a blind spot in drug labeling for persons with obesity. No, we’re not talking about the latest buzzy drug for treating obesity. Rather, we are talking about a prime example of labeling for other drugs that people with obesity may need when they face a serious […]
October 29, 2024 — In some ways, it is nothing new. The medical needs of people living with obesity have been dismissed seemingly forever. But at the same time it is shocking to learn of Merck – a highly respected pharmaceutical firm – leaving doctors in the dark by choice about how one of their drugs acts differently in […]
September 9, 2024 — The American College of Clinical Pharmacology is meeting in Bethesda this week. On the opening day, ACCP convened a symposium to address critical questions about how drugs work in people with obesity. What can we – industry, FDA, and scientists – do better? Because all too often, drug labels to guide safe prescribing are effectively […]